Hengyu Medical Secures Nearly RMB 100 Million in Funding to Advance Intravascular Imaging and Therapeutic Solutions

Investment Circle (ID: pedaily2012) December 8th, by reporter, recently, Horimed Technology Co., Ltd. (hereinafter referred to as "Horimed")Announced the completion of nearly 100 million yuan in financing.This round of financing was led byGuanghua Phoenix, Chengdu Sci-Tech Innovation InvestmentAndZhongtian WeiyeCo-investment.Star Bridge CapitalActing as the long-term exclusive financial advisor. This is another significant financing completed by Horimed in 2025, which will further accelerate the company’s research, development, production, and commercialization of vascular interventional imaging and treatment-related products.

Horimed Technology Co., Ltd., established in 2016 in Tianjin, focuses on the independent research, production, and sales of Intravascular Ultrasound (IVUS) equipment and catheters, Optical Coherence Tomography (OCT) equipment and catheters, dual-catheter systems integrated with IVUS/OCT, Fractional Flow Reserve (FFR) platforms based on IVUS and OCT, single-source dual-modality OCT-NIRS technology combining OCT and Near-Infrared Spectroscopy (NIRS), and intravascular laser plaque ablation technology. The company has mastered optical, ultrasound, and catheter platform technologies and continues to innovate globally based on core technologies, aiming to provide an integrated pan-vascular solution based on imaging products for medical professionals and patients.

Horimed has been deeply engaged in the field of intravascular ultrasound (IVUS) and optical coherence tomography (OCT) technology for many years, forming a full-chain layout from core components to complete equipment, and from single products to systematic solutions.。Horimed is one of the few companies in China that simultaneously masters the two core technologies of IVUS and OCT. This capability of running a "dual-technology route" in parallel has enabled Horimed to occupy a unique position in the field of precise vascular interventional diagnosis and treatment. The successful integration of OCT and Near-Infrared Spectroscopy (NIRS) into a single-source dual-modality OCT-NIRS technology has further allowed Horimed to establish a tri-modality imaging mode of OCT/IVUS/NIRS, providing a more comprehensive solution for clinical diagnosis and treatment.

Guanghua Wutong Managing Director Xiang WentianIndicates:"China has a large base of patients with coronary artery disease, and the volume of PCI surgeries continues to grow rapidly. With the significant increase in the clinical penetration rate of intravascular imaging technology, the market is ushering in unprecedented development opportunities. Horimed has been deeply engaged in the field of precise diagnosis and treatment for vascular intervention. As one of the few companies in China that simultaneously masters both ultrasound and optical core technology platforms, it has continuously launched innovative products with independent intellectual property rights, demonstrating outstanding technological advancement and industry leadership. We believe that Horimed will continue to achieve technological breakthroughs and commercial growth, and is expected to exert a strong industrial cluster effect, attracting more upstream and downstream supporting enterprises and high-end medical device innovation resources to Wenjiang. This will help build a more complete and dynamic medical industry ecosystem locally, injecting new momentum into regional high-quality development."

Relevant Responsible Person of Chengdu Kechuang InvestmentRepresentation:"This investment in Horimed is an important part of Chengdu Science and Technology Investment Group's layout in vascular interventional endoluminal imaging. We are optimistic about the company’s strong technical foundation in the cardiovascular field and its deep insights and forward-looking arrangements in the vascular disease diagnosis and treatment market. We look forward to future collaboration between both parties, further promoting the improvement and upgrading of related industrial chains in Chengdu."

Zou Feng, Star Bridge CapitalRepresentation："Horimed has completed two rounds of financing consecutively within the past year, reflecting the capital market's continued recognition of the clinical value of 'endovascular imaging platform solutions (IVUS/OCT/ICE)'. Guided by clinical needs, the company is driving the iterative upgrade of its product portfolio, strengthening its scaled manufacturing capabilities, and accelerating commercial scale-up through evidence-based data and penetration into leading centers, gradually building itself into a platform enterprise. In the future, with the support of capital, Horimed is expected to further enhance the accessibility and coverage of its innovative products, benefiting a broader patient population."